MCK Valuation Metrics
MCK Stock Price Metrics
MCK Dividend Metrics
MCK Growth Rate Metrics
MCK Discounted Cash Flow Metrics
| Fair Value Price | $1283.79 |
| Margin of Safety | 71.03% |
MCK Revenue Metrics
MCK PE Ratio Metrics
| PE Ratio | 19.51 |
| PE Ratio Avg TTM | 26.82 |
| PE Ratio Avg 3Y | 24.60 |
| Current VS TTM Avg | -27.27% |
| Current VS 3Y Avg | -20.69% |
| Current VS 5Y Avg | -25.18% |
MCK PS Ratio Metrics
| PS Ratio | 0.23 |
| PS Ratio Avg TTM | 0.26 |
| PS Ratio Avg 3Y | 0.24 |
| Current VS TTM Avg | -10.67% |
| Current VS 3Y Avg | -2.90% |
| Current VS 5Y Avg | +8.77% |
MCK PB Ratio Metrics
| PB Ratio | 4.98 |
| PB Ratio Avg TTM | 4.64 |
| PB Ratio Avg 3Y | 3.55 |
| Current VS TTM Avg | +7.25% |
| Current VS 3Y Avg | +40.26% |
| Current VS 5Y Avg | +37.15% |
MCK Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 15.52 |
| PFCF Ratio Avg TTM | 14.90 |
| PFCF Ratio Avg 3Y | 16.94 |
| Current VS TTM Avg | +4.16% |
| Current VS 3Y Avg | -8.40% |
| Current VS 5Y Avg | +7.44% |
MCK Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 1.85 |
| Debt/Equity Ratio Avg TTM | 1.40 |
| Debt/Equity Ratio Avg 3Y | 1.09 |
| Current VS TTM Avg | +32.62% |
| Current VS 3Y Avg | +69.72% |
| Current VS 5Y Avg | +70.77% |
MCK PEG Ratio Metrics
| PEG Ratio | 0.46 |
| PEG Ratio Avg TTM | 1.11 |
| PEG Ratio Avg 3Y | 0.76 |
| Current VS TTM Avg | -58.74% |
| Current VS 3Y Avg | -39.74% |
| Current VS 5Y Avg | -20.00% |
MCK FCF Yield
| FCF Yield | 6.44% |
| FCF Yield Avg TTM | 6.93% |
| FCF Yield Avg 3Y | 5.84% |
| Current VS TTM Avg | -7.09% |
| Current VS 3Y Avg | +10.27% |
| Current VS 5Y Avg | -10.98% |
MCK Earnings Yield
| Earnings Yield | 5.13% |
| Earnings Yield Avg TTM | 3.72% |
| Earnings Yield Avg 3Y | 4.25% |
| Current VS TTM Avg | +38.03% |
| Current VS 3Y Avg | +20.82% |
| Current VS 5Y Avg | +24.79% |
MCK EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 15.18 |
| Ev/Ebit Ratio Avg TTM | 22.79 |
| Ev/Ebit Ratio Avg 3Y | 19.84 |
| Current VS TTM Avg | -33.40% |
| Current VS 3Y Avg | -23.51% |
| Current VS 5Y Avg | -15.87% |
MCK EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 13.79 |
| Ev/Ebitda Ratio Avg TTM | 18.13 |
| Ev/Ebitda Ratio Avg 3Y | 16.26 |
| Current VS TTM Avg | -23.94% |
| Current VS 3Y Avg | -15.22% |
| Current VS 5Y Avg | -11.18% |
MCK EV/Assets Ratio Metrics
| Ev/Assets Ratio | 1.18 |
| Ev/Assets Ratio Avg TTM | 1.27 |
| Ev/Assets Ratio Avg 3Y | 1.16 |
| Current VS TTM Avg | -7.41% |
| Current VS 3Y Avg | +1.30% |
| Current VS 5Y Avg | +16.07% |
MCK EV/Sales Ratio Metrics
| Ev/Sales Ratio | 0.24 |
| Ev/Sales Ratio Avg TTM | 0.27 |
| Ev/Sales Ratio Avg 3Y | 0.25 |
| Current VS TTM Avg | -11.64% |
| Current VS 3Y Avg | -5.04% |
| Current VS 5Y Avg | +4.52% |
MCK Current Ratio Metrics
| Current Ratio | 0.85 |
| Current Ratio Avg TTM | 0.88 |
| Current Ratio Avg 3Y | 0.90 |
| Current VS TTM Avg | -2.86% |
| Current VS 3Y Avg | -5.29% |
| Current VS 5Y Avg | -8.44% |
MCK Quick Ratio Metrics
| Quick Ratio | 0.49 |
| Quick Ratio Avg TTM | 0.51 |
| Quick Ratio Avg 3Y | 0.51 |
| Current VS TTM Avg | -3.92% |
| Current VS 3Y Avg | -3.92% |
| Current VS 5Y Avg | -8.13% |
MCK ROIC Metrics
| ROIC | 31.48% |
| ROIC Avg 3Y | 24.73% |
| ROIC Avg 5Y | 20.68% |
| Current VS 3Y Avg | +27.29% |
| Current VS 5Y Avg | +52.20% |
| Current VS 10Y Avg | +88.87% |
MCK Return on Assets Metrics
| ROA | 5.78 |
| ROA Avg TTM | 5.08 |
| ROA Avg 3Y | 5.08 |
| Current VS TTM Avg | +13.67% |
| Current VS 3Y Avg | +13.72% |
| Current VS 5Y Avg | +129.52% |
MCK Return on Equity Metrics
| ROE | (219.24) |
| ROE Avg TTM | (189.06) |
| ROE Avg 3Y | (180.53) |
| Current VS TTM Avg | +15.97% |
| Current VS 3Y Avg | +21.44% |
| Current VS 5Y Avg | -106.31% |
MCK Net Profit Margin Metrics
| Net Profit Margin | 1.18% |
| Net Profit Margin Avg TTM | 1.05% |
| Net Profit Margin Avg 3Y | 1.09% |
| Current VS TTM Avg | +12.38% |
| Current VS 3Y Avg | +8.26% |
| Current VS 5Y Avg | +146.69% |
Last Updated: Friday, June 19, 2026
About McKesson Corporation
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Brian S. Tyler